Skip to content
Screener

Krystal Biotech, Inc. KRYS Business Segments — SG&A

Similar metrics at other companies

Silicon Laboratories logo
SLABReportable Segment — SG&A
$55.49M+33.3%
Indivior Pharmaceuticals, Inc. logo
INDVReportable Segment — SG&A
$124M-6.8%
VGN
VGNTReportable Segment — SG&A
$97M-7.6%
BridgeBio Pharma logo
BBIOReportable Segment — SG&A
$163.9M+54.1%
QXO, Inc. logo
QXOReportable Segment — SG&A
$457.8M+1,792%
Agios Pharmaceuticals logo
AGIOReportable Segment — SG&A
$51.55M+12.4%

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$9.64B+145%
Enterprise value$9.15B+155%
P/E42.9×+16.0×
P/S23.1×+12.2×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0×0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 7:06 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001711279-26-000043
(in thousands)Three Months Ended / March 31, 2026March 31, 2025
Other research programs736692
Other research and development costs (1)7,7876,997
Total research and development15,33114,256
Selling, general and administrative41,01432,647
Income from operations$53,689$36,252
Other income
Interest and other income, net7,7537,345
Income before income taxes$61,442$43,597

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Krystal Biotech, Inc.'s business segments — SG&A?
Krystal Biotech, Inc. (KRYS) reported business segments — SG&A of $41.01M in Q1 2026.
How has Krystal Biotech, Inc.'s business segments — SG&A changed year-over-year?
Krystal Biotech, Inc.'s business segments — SG&A increased by 25.6% year-over-year, from $32.65M to $41.01M.
What is the long-term trend for Krystal Biotech, Inc.'s business segments — SG&A?
Over 2 years (2023 to 2025), Krystal Biotech, Inc.'s business segments — SG&A has grown at a 22.2% compound annual growth rate (CAGR), from $98.29M to $146.83M.
What does business segments — SG&A mean?
Selling, general, and administrative expenses encompass the costs of supporting the segment's commercial operations, including marketing, sales force, legal, and corporate overhead. These costs reflect the operational infrastructure required to bring products to market and manage the business.

Ask your AI about Krystal Biotech, Inc.'s business segments — sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude